The analysis of the function and the clinical application of REIC/ Dkk-3 gene in digestive organ cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09001
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Okayama University
• Principal Investigator: Kato Hironari 岡山大学, 大学病院, 助教 (60619039)
• Co-Investigator(Kenkyū-buntansha): 内田 大輔 岡山大学, 大学病院, 医員 (50749215) ; 白羽 英則 岡山大学, 大学病院, 講師 (40379748) ; 那須 保友 岡山大学, 医歯薬学総合研究科, 教授 (20237572) ; 堤 康一郎 岡山大学, 大学病院, 助教 (40610910) ; 松下 浩志 岡山大学, 医学部, 客員研究員 (20786107) ; 岩室 雅也 岡山大学, 大学病院, 助教 (30645403)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 遺伝子治療 / REIC / DKK3

Outline of Final Research Achievements

The reduced expression in immortalized cells REIC/the dickkopf 3 (Dkk-3) gene induced cancer selective apotosis in cell lines of hepatocellular carcinoma and cholangio cell carcinoma. REIC/Dkk‐3 expression was decreased in resected HCC tissues by immunohistochemical staining.
The REIC/DKK3 protein and peipheral blood mononuclear cells synergistically enhanced anticancer immunological effects against pancreatic cancer cells.
The clinical trial of REIC/DKK3 gene therapy for the patients with hepatocellular carcinoma started.

Free Research Field

消化器内科学